Drug-light combo could offer control over CAR T-cell therapy

UC San Diego bioengineers are a step closer to making CAR T-cell therapy safer, more precise and easy to control. They developed a system that allows them to select where and when CAR T cells get turned on so that they destroy cancer cells without harming normal cells. The system requires two “keys”—the drug Tamoxifen and blue light—to activate CAR T cells to bind to their targets. Just one key keeps the cells inactive.

Read more